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Abstract 
    Systemic lupus erythematosus (SLE) considered as one of the chronic auto-
immune multi systemic diseases affects females rather than males especially during 
childbearing age. A  fluctuating nature of SLE disease activity deprive  this disease 
from any of monitoring test,  at  likewise both of  SLE  disease activity index 
(SLEDAI) criteria or even the laboratory analyses do not confirm such disease 
activity, especially when a patient have normal serological results although during the 
disease activity (flare). This study done as a case control study (retrospective study), 
where a total sample size included (86) freshly peripheral blood samples, which  
subdivided into: a first the disease group  comprised from (66) blood samples 
voluntary obtained from SLE patients whose attended Al-Yarmouk teaching hospital 
and Al-karama teaching hospital during the period (October/2017-June/2018) after 
official approvals were obtained from health institutions. however,  the disease group 
were be divided into active group (flare) and in active group (remission) according to 
SLE disease activity index (SLEDAI) criteria by a specialized consultant.   while the 
second group included (18) blood samples obtained from  healthy individuals 
(controls) whose matched with a disease group in gender and age.  
     This study based on an immunological  evaluation of ( CD69 upon CD3
+
 ratio) 
percentages at peripheral blood T-lymphocytes tested as SLE disease activity 
monitoring marker, owing to that  purpose these markers (CD69/CD3
+
)  were be 
isolated from freshly blood T-lymphocytes. therefore were be analyzed by 
Immunophenotyping flow cytometer of multi-color immunofluorescent staining.  
Whereas such ratio ( CD69 upon CD3+ marker) obtained from  data analysis (CY 
flow is the software part of flow cytometer). such ratio set up  (CD69/CD3) test  as 
Comparing with other laboratory analyzes to investigate the activity of SLE disease 
mentioned as; Anti-nuclear antibodies test, Anti-double stranded-DNA antibodies test, 
as well as SLE activity index scores. Furthermore thatCD69 type II of C-lectin 
membrane bound receptor, described as early activation marker for T-lymphocytes, 
that tested for such aim while the results gave insurance about over expression of 
CD69 upon CD3
+
 T-cells for the  active (flare) group with a highly significant  (P 
value= 0.0001).While healthy controls have (P value=0.05) as having no significant 
level.  
      Also there was a hallmark among this study groups between (CD69 upon CD3+) 
ratio and age as intervals of (9) years, such ratio markedly elevated at (21and59 years) 
that have a highly significant differences (p value=0.0001), at another word systemic 
lupus erythematosus disease effect females at highly significant (P value= 
0.0001).anti-nuclear anti bodies (ANA) test signified a positive correlation of disease 
group CD69 upon CD3+ blood T-cells highly significant differences (p value=0.0001) 
within low significant level, But (ds-DNA) test indicated   low significant differences 
with( CD69 upon CD3+ blood T-cells ratio) of the disease group. Moreover the most  
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important indicative parameter  for disease activity that systemic lupus erythematosus 
disease activity index whereas the (CD69 upon CD3+) ratio   a positive correlation 
matching with SLEDAI score  for SLE disease groups, furthermore that active group 
registered elevated  levels (mean ±SD = 30.07±1.89, and the mean=30.00) 
respectively at (8) and (9) scores. In conclusion According to these results which have 
been showing that CD69 gave a vigorous indication as early activating marker for 
revealing the activity of SLE disease rather than SLEDAI which consider as a real 
time of the clinical manifestations appearance. 
Key Words: Systemic lupus Erythematosus, CD69 percentage, CD3 percentage, 
Anti-nuclear Abs, SLEDAI. 
Introduction  
     Systematic lupus erythematosus (SLE) can be defined as a chronic systemic 
inflammatory autoimmune disorder (Syh.Jae et al., 2017).Characterized by 
impairment within tolerance to the self-antigen and formation of many different auto-
antibodies with the ability to attack multiple organs, and systems, including the blood 
vessels, skin, kidney, nervous system (Vitales-Noyola et al., 2017),Thus, In patients 
of systemic lupus erythematosus the pathogenicity consider as a complex condition 
and the loss of tolerance to self -antigen due to the consequence of multiple genetic 
risk factors, environmental effectiveness, deficiency in immune regulatory 
mechanisms (Noyola et al., 2017;Novelli et al., 2018), as well as the gender specially 
effects women at child-bearing age (Wigrenet al., 2015). The complex nature of 
(SLE) disease described as unpredictable characteristic and fluctuating course. In 
spite of developing methods for disease activity measurement but still lack of consent 
around the optimum criteria about (SLE) remission as well as flare (Medina-Quiñones 
et al., 2016).  
   There is a problem in (SLE) patients monitoring mainly exist at the determine 
disease activity, due to the contradiction in serological parameters which sometimes 
give normal values while The signs and symptoms have shown clearly appearance in 
(SLE) patients, (Saber et al.,2007).T-cells consider as a key player in (SLE) disease, 
because of their helpful effects that inducing auto-reactive B cells, also their ability to 
escape into objective organs and tissues causing their harmful effects; thus, T-
lymphocyte at most importance not only in evaluating disease activity, 
pathophysiology; but also for characterize predictive biomarkers as well as most 
medication targets (Moulton et al., 2011).CD69 expression is the earliest induced 
marker on the T-lymphocyte surface after TCR/CD3 complex activation, this 
expression and appearance of CD69 on plasma membrane of the activated 
lymphocytes is go faster than expression of CD25 (Cibriàn et al., 2017). The 
expression of CD69 on T-cells surfaces at peripheral blood may give a novel insight 
indicator about monitoring of early activated T-cells population leading to level of T-
cell mediated immune responses can also be expected in the body (Su et al., 1997). 
Materials and Methods 
Study population:  
    Whole samples population of such study were (86) individual samples subdivided 
into the first part "Disease group" that included (Active group and Inactive group) 
their samples obtained from both of (In-patients and out-patients) whom attended Al-
SHAFAA DIALYSIS CENTER, The Consultancy Clinics of AL-Yarmouk Teaching 
Hospital. As well as patients who attended Al-Hayat Dialysis Center, Al-Karama 
teaching hospital.Whereas a second part of the study were "Healthy group" obtained 
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from selected (18) healthy voluntaries individuals. during the period  (October/2017-
June/2018). As the following details: 
(a) Disease group: sub-divided according to SLEDAI into: 
(a1) Active group (disease flare):  The samples were being obtained from 
(32)patients; (1)male and (31) female  with aging ranged(13-60years) systemic lupus 
erythematosus (SLE) patients diagnosed according to disease activity assessed with 
[(SLEDAI) SLE Disease Activity Index] by specialized physicians. 
(a2)Inactive group (SLE remission): these Samples were obtained from (36) 
patients; (3) males /(33) females with aging ranged (13-60years) diagnosed by a 
specialized physicians as SLE patients within remission status according to 
(SLEDAI). 
(b) Healthy control group: The samples were being obtained from the (18) healthy 
Individuals (2) males, (16) females their age ranged (13-60years) volunteer after take 
their conceptions. All samples were being tested which gave absolutely healthy 
condition insurance. 
Samples collection:  
    All samples have been collected at the same manner from each individual, which 
described as about (5ml) of whole venous blood have been collected under sterile 
conditions; then they were subdivided into the followings: 
 About (2.5ml) of whole venous blood poured into heparin tube for CD3 & 
CD69 flow cytometric analyses. 
 About (2.5ml) of whole blood poured into plane tube, waiting until blood 
clotting ;then must be centrifuged about (3000rpm) for (3minutes) in order to 
separate a serum from clotted blood, the serum were be isolated by micropipette 
and separated for ANA, and ds-DNA testsabout (1ml) poured into a plane tube 
then stored at (-20˚C). 
That CD3 and CD69 are both used as vitro identification for both CD markers 
cell expression antigens diagnosed by BD FACs™ brand flow cytometer. 
Flow cytometer: one improved table flow cytometer (Cy Flow) instrument used for 
detecting and analyzing of T-lymphocytes CD3 and CD69 markers, that must be 
equipped for appropriate fluorescence laser excitation at (405nm, 488nm, and 635nm) 
with appropriate software (Cy View) software for data acquisition as well as analysis. 
 flow- cytometer kits:Ι- CD3(SK7) monoclonal mouse anti-human, Π -PE 
Mouse Anti-Human CD69Becton, Dickinson and company BD Bioscience, BD 
Bioscience Pharmingen™/USA. 
 Procedure: About 20ml from both of CD3 fluorochrome- conjugated   
monoclonal- antibody and CD69 fluorochrome-conjugated monoclonal 
antibody to 100ml of freshly whole blood in (12x75-mm) capped   polystyrene    
test tube; at the same time.Thoroughly vortexes and incubated 15-30 minutes in 
the dark place at room temperature (20°C-25°C) 
-About 2ml added of 1x BD FACS lysine solution, then  thoroughly vortex 
and incubated for 10 minutes in dark place at room temperature.Tube 
centrifugation at 300g (gravity=1500rpm) for 5minutes .Washing (3times) by 
adding buffer solution, discharging supernatant .Add (2ml) from (FITC) 
solution into the tube. 
 Appropriated place for single test tube in the Partec Cy Flow® instrument; 
each tube place on appropriated place and tested the resultsappeared on the 
specific data show within special program named as (Cy View software). 
Al-Kufa University Journal for Biology / VOL.10 / NO.2 / Year: 2018                                     
                       Print ISSN: 2073-8854                Online ISSN: 2311-6544  
 
 
55 
 
 
Whereas Anti-double stranded DNA, Anti-nuclear antibody tested by using 
Immunofluorescence technique: 
Indirect- Immunofluorescence the samples were incubated with antigen substrate 
while unreacted antibodies washed off; such substrate incubated within conjugate 
labeled with specific fluorescein; slides viewed under fluorescence microscope  
while auto antibodies give  an apple green fluorescence appearance according 
to(CDC). 
 Immunofluorescence kits :Ι-  NOVA lite ANA plus mouse kidney 
&stomach, Π -NOVA lite ds-DNA Crithidialuciliae, A werfern  company 
/USA. 
 
Procedure:  
 First step all samples and reagents must be placed until reached at room 
temperature (20-26˚C). 
 all samples must be mixed by Vortex. 
 reagents must be mixed gently. 
 A warning; the slides must be never dried. 
 Adding samples after dilution by PBS into wells of the slides, then  The slides 
incubated in appropriated suitable moist chamber for 30±5 minutes.then 
washing by diluted washing buffer, After excess PBS shaken off ; the slides 
retained onto the humid chamber, immediately cover each well with one drop of 
fluorescent conjugate, then incubated 30±5, At the same manner of  step5 
repeated for 3 times, A cover slip placed on a paper towel. Mounting medium 
placed in a continuous line to the bottom edge of the cover slip. Excess PBS 
must be removed then cover slip placed by touching the lower edge. 
 Those done for all positive samples by making serial (2 fold) dilutions from 
initial screening dilution (i.e. 1:40, 1:80 …1:5120). 
 The fluorescence grade determined by using the below criteria: 
 )+1)Lowest specific fluorescence that provide clear differentiation of 
nuclear or/and cytoplasmic staining from the background fluorescence. 
 (+2)Positive clear differentiated fluorescence. 
 )+3) Bright apple green fluorescence. 
 (+4)Brilliant apple green fluorescence. (Loveridge  et al., 1980) 
Statistical analysis:  
   Analyses of data were carried out using the available statistical package of SPSS-24 
(Statistical Packages for Social Sciences- version 24). Data were presented in simple 
measures of frequency, percentage, mean, standard deviation, and range (minimum-
maximum values).The significance of difference of different means (quantitative data) 
were tested using Students-t-test for difference between two independent means or 
Paired-t-test for difference of paired observations (or two dependent means), or 
ANOVA test for difference among more than two independent means. The 
significance of difference of different percentages (qualitative data) was tested using 
Pearson Chi-square test (χ2-test) with application of Yate's correction or Fisher Exact 
test whenever applicable. Statistical significance was considered whenever the P 
value was equal or less than (0.05), (Danielet al., 2012). 
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Results: 
 Patients with SLE disease (66) freshly blood samples, whereas active group were 
(32) samples, while in-active group were (36) samples, finally health controls were 
(18) samples. There were a significant differences represented on the following tables: 
 
Distribution of studied groups according to age & gender:the study groups were 
be divided into four age group  (interval of 9 years) the main age group of SLE 
patients were (40-49 years) represented on (table 1). 
Table 1: general distribution of studied groups according age and gender 
 
Frequency of CD69/CD3
+
T-cells % Expression among the study groups: table(2) 
shows a general statistical parameters  about CD69/CD3
+
%T-cells as differentiated 
marker among tested groups there were a highly significant differences according to 
(p value=0.0001) between active and inactive groups, as well as among groups at (p 
value=0.0001, when p 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
parameters 
Disease group 
(68) 
 
Healthy 
group 
(18) 
 
 
   P- 
value 
 
Active 
group 
(32) 
In-active 
group 
(36) 
 No % No % No %  
Age 
(years) 
<30 3 9.3 3 8.3 3 16.7 0.894 
30---39 8 25.0 10 27.8 3 16.7  
40---49 15 46.9 14 38.9 7 38.9  
=>50 6 18.8 9 25.0 5 27.7  
 total 32 100 36 100 18 100  
Gender Male 1 3.1 3 8.3 2 11.1 0.520 
Female 31 96.9 33 91.7 16 88.9  
*Significant difference between proportion using Pearson Chi-square test 
at 0.05 level 
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Table 2: case control differences depending on CD69/CD3
+
 T-cells% Expression 
 
CD69/CD3+T-cells ratio frequency among studied groups according to ANA test 
& ds-DNA test grads: the frequency of CD69/CD3+% T-cells for the studied groups 
according to ANA, and ds-DNA tests grades, those records a positive correlation of 
CD69/CD3+% within grads of both ANA at highest (mean ±SD, active 29.26±1.78, in 
active 17.02±7.20) at (3+) grade, as well as ds-DNA tests at highest (mean ±SD, 
active28.41±3.23, inactive23.37±2.10) at (3+) grade. While negative score gave a 
significant value among studied groups for both ANA and ds-DNA tests on( table 3). 
 
 
 
 
 
 
 
 
 
 
CD69/CD3
+
% Active 
(Flares) 
Non-Active 
(Remission) 
Healthy 
(controls) 
 Number 32 36 18 
Mean ±SD 23.08±8.37 13.73±5.21 1.52±0.97 
Standard Error of Mean 1.480 0.868 0.230 
Percentile 05
th
 7.45 8.36 0.25 
50
th
 
(Median) 
27.00 12.20 1.48 
75
th
 29.76 18.00 2.38 
99
th
 32.00 26.00 3.34 
 P value compared to 
healthy control 
0.0001* 0.0001* - 
 P value compared to 
Remission 
0.0001* - - 
 P value compare All 
groups 
0.0001#   
*Significant difference between two independent means using Students-t-
test at 0.05 level. 
#Significant difference among more than two independent means using 
ANOVA test at 0.05 level. 
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Table 3:comparisons table ofCD69/CD3+T-cells ratio frequency expressing on 
study groups according to ANA test and ds-DNA test 
 
 
parameters CD69/CD3
+
% 
Active 
(Flares) 
Non-Active 
(Remission) 
Healthy 
control 
P 
value 
No Mean± 
SD 
(Range) 
No Mean± SD 
(Range) 
No Mean± 
SD 
(Range) 
ANA Negative 1 6.83± 1 11.33± 18 1.52±0.
97 
(0.25-
3.34) 
0.000
1# 
[+] 17 21.91±8
.89 
(7.45-
32.0) 
19 11.90±3.8
3 
(6.95-
20.97) 
  0.000
1* 
[++] 8 22.97±7
.32 
(7.86-
31.14) 
10 15.50±5.3
9 
(9.50-
26.0) 
  0.024
* 
[+++] 6 29.26±1
.78 
(26.0-
31.0) 
6 17.02±7.2
0 
(8.90-
25.0) 
  0.002
* 
P value  0.052  0.101    
Ds-
DNA 
Negative 8 9.82±2.
92 
(6.83-
15.34) 
28 11.44±2.8
6 
(6.95-
19.0) 
18 1.52±0.
97 
(0.25-
3.34) 
0.000
1# 
[+] 10 28.36±2
.41 
(24.0-
32.0) 
3 19.00±2.0
0 
(17.0-
21.0) 
  0.000
1* 
[++] 9 26.05±3
.73 
(19.0-
30.10) 
2 23.49±3.5
6 
(20.97-
26.0) 
  0.401 
[+++] 5 28.41±3
.23 
(23.0-
31.14) 
3 23.37±2.1
0 
(21.0-
25.0) 
  0.055 
P value  0.0001#  0.0001#    
*Significant difference between two independent means using Students-t-test at 
0.05 level. 
#Significant difference among more than two independent means using 
ANOVA test at 0.05 level. 
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CD69/CD3+T-cells ratio frequency among studied groups according to SLE 
disease activity index (SLEDAI) scores:The most important evaluating parameter is 
SLE disease activity index (SLEDAI), which displayed on table (4). whereas the 
studied groups distributed according to SLEDAI scores ranged (0-9) scores for each 
of studied groups (Active, In active, healthy controls). Likewise, although most active 
group patients stilled at score (4),but the (Mean ± SD) significantly positively 
corresponds with SLEDAI scores whereas reached at peak value of this study at (9) 
score 
Table 4: comparisons table of CD69/CD3+T-cells ratio frequency expressing on 
study groups according to SLE disease activity index (SLEDAI) scores. 
 
 
 
 
 
 
 
 
 
 
 
CD69/CD3
+
% 
SLEDAI 
Scores 
Active (Flares) Non-Active 
(Remission) 
Healthy 
control 
P 
val
ue  No 
 
Mean ±SD  
(Range) 
No Mean ±SD 
(Range) 
N
o 
Mean 
±SD 
(Range) 
0 - - 3 13.66±0.15(
13.5-13.8) 
1
8 
1.52±0.9
7(0.25-
3.34) 
0.0
001
* 
1 - - 10 9.99±1.79 
(6.95-12.73) 
   
2 - - 11 14.35±5.00 
(8.90-21.0) 
   
3 - - 12 16.31±6.37 
(8.36-26.0) 
   
4 11 16.01±7.48 
(7.45-26.4) 
- -    
5 6 21.90±9.94 
(6.83-31.0) 
- -    
6 4 26.13±2.78 
(22.0-28.0) 
- -    
7 5 29.26±0.78 
(28.0-29.8) 
- -    
8 5 30.07±1.89 
(27.0-32.0) 
- -    
9 1 30.00± - -    
0.002# 0.033#    
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the correlation between CD69/CD3
+
%T-cells with SLEDAI scores showed no shared 
points among the studied groups which displayed on  Figure (1) as following: 
 
Fig. 1: Linear Regression of CD69/CD3
+
 depending on SLEDAI scores for each of 
SLE active group that indicated highly significant positive correlation while SLE in 
active g group low significant positive correlation.  
 
Discussion:    
    The present study detects SLE disease age  ranged (21-59 years)  among samples of 
SLE disease group patients. These results corresponds with Al-Haidary  (2004)  peak 
range of SLE Iraqi patients(20-69 years), while (14-61 years) by Al-Saady (2010), 
also This study results corresponds with Arabs 'researches disease like Al Dhanhani et 
al.(2017) reported about Arab United Emirates mean age (mean ±SD=28.6± 12.4 
years), also Al youssuf et al.(2016) in Saudi Arabia SLE disease (mean age 
onset=29.3 years). Moreover Ku et al.(2016), referred to range of Chine's' women age 
was (9-40).  
   More farther this study confirmed within a peripheral blood CD69/CD3+%upon T-
cells as SLE disease activity indicator,CD69/CD3+% T-cells population described by 
Saber et al. (2007) as a much informative about CD69 expression receptor, whereas  
also explained by Vitales-Noyola et al. (2017) as a stimulator molecule involved 
activation of various  immune cells.Therefore; a current study presents an actual 
considered differences among groups under study depending on CD69/CD3+T-cells 
ratio as immunological marker which pointed a highly significant correlation (p value 
0.0001) with SLE disease activity, that played as an early inducible marker for T-
lymphocytes activation as well as migration, Radulovic et al. (2013). our results 
approved with Martin et al.(2010) whose reported about SLE patients whereas  
ensured that CD69 considered as early activation receptor within an intrinsic 
differentiation program where determined immune inflammatory process. Whereas 
the previous researchers results corresponds with a current study, like Su et al.(1997)  
and Syh.Jae et al.(2017).Anti-nuclear anti-bodies test remains essential for SLE 
patients that may be assess on predicting the clinical patterns of SLE disease and its 
prognosis Ahmed  et al.(2017) while Perumalla et al.(2016) mentioned the test as 
diagnostic SLE criteria, but also pointed about lupus ANA negative 
patients.According to the present study that signaled as a highly significant among the 
groups with (p value 0.0001), where may be represented as a diagnostic tool through 
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giving early indication, also signify between active vs. inactive as highly (p value; 
0.0001, 0.024, 0.002, respectively), which may giving an indication about the highly 
correlation between elevated CD69/CD3+%T-cells of peripheral blood with 
increasing anti-nuclear anti-bodies levels as a result of T-cells activity which 
described by Moulton et al.(2011) as provides supporting for B-cells auto reactivity 
whereas Pisetky et al.(2018) disagreed this study about ANA test whose considered 
such test as independent  indication about disease activity but corresponds with this  
results about ds-DNA test, which  gave a sufficientdifferentiation between active vs. 
inactive SLE patients, whereas the measuring  of ds-DNA Abs may be giving a 
potential helpful biomarker for SLE disease activity assessment by Xu et al.(2018), 
but our results shows no any significant correlation within disease activity, that may 
be explained by Su et al.(1997) as the correlation of anti-double stranded DNA Abs 
with disease activity reflects impairment, when SLE clinical activity not absolutely 
products of B-cells alone, the activation of T helper2 capable to direct the reaction 
toward humeral immunity additionally to their effects on B-cells activation and Abs 
production, which observed in central nervous system lupus patients have been 
reported within elevated SLEDAI scores but low anti-double stranded DNA titers.  
Additionally, Anand et al.(2002), whose corresponds these results also referred about 
subpopulation T-cells; (CD3+ CD4- CD8-, and double negative dendritic T-cells) 
which highly expressed CD60 that enhancing anti-DNA auto-antibodies production. 
Which gave an explanation about lost correlation between ds-DNA and 
(CD69/CD3+T-cells%). Finally, also the results corresponds with Compagno (2015) 
about ds-DNA.Actually, SLE disease activity index was a basic requisite for 
CD69/CD3+% T-cells evaluation test whereas successfully signify a highly 
correlation with its scores reached to (mean ±SD ˃30± %) at (9) score. also besides 
that disease activity assessed by measuring SLEDAI scores, while "weighted average 
of SLEDI scores>10" by Kakati et al.(2015), whose observed the correlation between 
numbers of flares and SLEDAI scores, where the sum of the clinical appearance 
described as "flare". Therefore, this study patients selected within the scores lower 
than (average ˃10 score) in order to investigate the early activation process prior 
disease flare. Anyway SLEDAI described by Yee et al.(2011) as the index condensed 
on recurrent or the new manifestations but failed to capture earliest activity (on-going 
activity).  However that SLE patients (flare) within disease activity initially at score 
(4), while the peak at score at (9) according to  this study. There were many 
researcher investigated the SLEDAI with CD69/CD3+T –cells such as, Saber et 
al.(1997), Su et al.(2007), Vitales-Noyola et al.(2017), and Hervier et al.(2011). 
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